IL-15

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), National Cancer Institute (NCI), Masonic Cancer Center, University of Minnesota

Conditions

Acute Myelogenous LeukemiaHIV InfectionsMetastatic MelanomaSkin Cancer

Phase 1

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

CompletedNCT00528489

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2007-10-31End: 2010-01-31Updated: 2021-10-14

Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

TerminatedNCT01369888

National Cancer Institute (NCI)Metastatic Melanoma, Skin Cancer

Start: 2011-05-31End: 2014-05-31Updated: 2015-01-27

Phase 2

MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

CompletedNCT02395822

Masonic Cancer Center, University of MinnesotaAcute Myelogenous Leukemia

Start: 2015-10-01End: 2016-12-01Updated: 2018-02-20

Related Papers

IL-15 in the Combination Immunotherapy of Cancer.

2020-05-19183 citations

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

Blood Advances2019-07-02225 citations